Co-Diagnostics Announces That Its JV CoMira Diagnostics Finalized A Lease Agreement For Its Planned Manufacturing Facility In Saudi Arabia

he lease execution represents a key milestone as CoMira advances domestic manufacturing capabilities within the KSA and follows the Company's previously announced approval for an industrial land allocation in Sudair Industrial City by the Saudi Authority for Industrial Cities and Technology Zones ("MODON").

"Co-Dx continues to advance our CoMira joint venture, with today's lease finalization marking an important milestone in expanding our presence in the KSA," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "Executing the lease moves us from planning into the execution phase of development and reflects ongoing progress in localizing our platform within Saudi Arabia. We believe this initiative supports the Kingdom's Vision 2030 goals related to healthcare infrastructure, domestic manufacturing, and supply-chain resilience."

The lease covers an industrial facility of approximately 14,400 square feet in Sudair Industrial City, one of Saudi Arabia's leading industrial hubs. The facility is designated for approved manufacturing activities, including diagnostic instruments, laboratory testing equipment, and medical consumables, and is intended to support CoMira's planned manufacturing activities related to the Co-Dx PCR platform* and other Co-Dx technology, subject to applicable regulatory approvals and operational requirements.

The turnkey nature of the facility is expected to support a more efficient transition to operational readiness compared to traditional ground-up development, aligning with the Company's focus on capital-efficient expansion.

Ihssan Rjoob, CEO of CoMira Diagnostics, remarked "Sudair Industrial City is intended to play a central role in Saudi Arabia's Vision 2030 initiative to diversify the economy and expand local manufacturing capabilities. We believe that establishing a presence within this industrial ecosystem aligns CoMira with national priorities around healthcare localization and industrial development."

CoMira is focused on establishing localized manufacturing and distribution capabilities across Saudi Arabia and the broader Middle East and North Africa (MENA) region. The Company believes that domestic production of molecular diagnostics within the Kingdom may offer strategic advantages, particularly in government procurement processes that prioritize locally manufactured healthcare solutions.

In addition, the Company believes that as relevant regulatory clearances are obtained by the U.S. FDA, the Co-Dx PCR platform may be introduced into the Saudi market through a more streamlined regulatory pathway compared to other international jurisdictions, potentially supporting earlier commercial activity as the facility is developed.

This announcement represents the latest step in Co-Diagnostics' broader strategy to deploy its platform globally through localized partnerships, including its CoSara joint venture in India, and reflects the Company's continued focus on scalable, capital-efficient international expansion.